Table 1 Baseline characteristics of early infliximab induction and delayed infliximab induction groups at infliximab initiation
Characteristics | Early infliximab induction (n = 73) | Delayed infliximab induction (n = 44) | p value |
|---|---|---|---|
Sex (male), n (%) | 56 (76.7) | 28 (63.6) | 0.128 |
Age at inclusion, years (IQR) | 25.0 (20.0–29.0) | 24.0(21.0–31.75) | 0.547 |
BMI, kg/m2 (mean ± SD) | 18.98 ± 2.77 | 19.12 ± 2.91 | 0.810 |
Mean disease duration, months (IQR) | |||
Luminal disease | 9.0 (1.0–39.0) | 4.5 (1.0–24.0) | 0.294 |
Perianal disease | 12.0 (3.0–35.0) | 19.0 (5.25–30.5) | 0.354 |
Smoking status, n (%) | 0.511 | ||
Non-smokers | 69 (94.5) | 39 (88.6) | |
Ex-smokers | 3 (4.1) | 4 (9.1) | |
Active smokers | 1 (1.4) | 1 (2.3) | |
Initial presentation of CD, n (%) | 0.029 | ||
Perianal | 40 (54.8) | 33 (75.0) | |
Luminal | 33 (45.2) | 11 (25.0) | |
Types of fistula, n (%) | 0.614 | ||
Anorectal | 68 (93.2) | 39 (88.6) | |
Invade to adjacent organa | 5 (6.8) | 5 (11.4) | |
Complex fistulas (AGA), n (%) | 66 (90.4) | 40 (90.9) | 1.000 |
Proctitis, n (%) | 18 (24.7) | 12 (27.3) | 0.828 |
Anorectal stricture, n (%) | 27 (37.0) | 9 (20.5) | 0.067 |
Presence of abscess at baseline, n (%) | 42(57.5) | 20(45.5) | 0.205 |
Previous perianal surgery, n (%) | 39 (53.4) | 22 (50.0) | 0.849 |
Disease behavior, n (%) | 1.000 | ||
B1-inflammation | 47 (64.4) | 28 (63.6) | |
B2-stricturing | 25 (34.2) | 16 (36.4) | |
B3-penetrating | 1 (1.4) | 0 (0) | |
Disease location, n (%) | 0.447 | ||
L1-ileal | 16 (21.9) | 10 (22.7) | |
L2-colonic | 10 (13.7) | 3 (6.8) | |
L3-ileocolonic | 40 (54.8) | 29 (65.9) | |
L4-upper gastrointestinal | 7 (9.6) | 2 (4.6) | |
Previous medical treatment, n (%) | 0.753 | ||
None | 31 (42.5) | 22 (50.0) | |
Infliximab | 2 (2.7) | 2 (4.5) | |
Immunomodulators | 10 (13.7) | 6 (13.6) | |
5-ASA | 30 (41.1) | 14 (31.8) | |